Neogap Therapeutics Reports First Patients Treated in Neogap Personalized Immunotherapy Trial

“We are delighted to have treated the first patients – this is a significant milestone in our clinical trial and our mission to develop curative treatments for critically ill cancer patients. We have an outstanding trial team and look forward to the upcoming results,” says Samuel Svensson, CEO of Neogap Therapeutics.